Related Experiment Video

Updated: Sep 3, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

Valproate plasma protein binding in the uremic condition

D Brewster, N C Muir

    Clinical Pharmacology and Therapeutics
    |January 1, 1980
    PubMed

    More Related Videos

    Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes11:47

    Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

    Published on: March 4, 2022

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    Related Concept Videos

    Drug Distribution: Plasma Protein Binding01:29

    Drug Distribution: Plasma Protein Binding

    Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
    Protein-Drug Binding: Mechanism and Kinetics01:16

    Protein-Drug Binding: Mechanism and Kinetics

    Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
    Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
    Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

    Factors Affecting Protein-Drug Binding: Protein-Related Factors

    Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
    The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
    Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

    Factors Affecting Protein-Drug Binding: Patient-Related Factors

    Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
    Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
    Hepatic Drug Clearance: Effect of Protein Binding01:09

    Hepatic Drug Clearance: Effect of Protein Binding

    Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
    For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
    Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

    Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

    When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
    To quantify the extent of bioavailability, pharmacologists often use a parameter called .